Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening

Rosenstock, J; Blonde, L; Aroda, VR; Frias, J; Souhami, E; Ji, C; Niemoeller, E; Del Prato, S

Rosenstock, J (corresponding author), Dallas Diabet Res Ctr Med City, 7777 Forest Lane,Suite C-685, Dallas, TX 75230 USA.

DIABETES OBESITY & METABOLISM, 2021; 23 (6): 1331

Abstract

Aim In people with type 2 diabetes (T2D) requiring intensification beyond glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and oral antihyperglyc......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索